Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

BACKGROUND: Despite numerous therapeutic options, safe and curative therapy is unavailable for most patients with chronic lymphocytic leukemia (CLL). A drawback of current therapies such as the anti-CD20 monoclonal antibody (mAb) rituximab is the elimination of all healthy B cells, resulting in impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cyr, Matthew G, Mhibik, Maissa, Qi, Junpeng, Peng, Haiyong, Chang, Jing, Gaglione, Erika M, Eik, David, Herrick, John, Venables, Thomas, Novick, Scott J, Courouble, Valentine V, Griffin, Patrick R, Wiestner, Adrian, Rader, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710465/
https://www.ncbi.nlm.nih.gov/pubmed/36442911
http://dx.doi.org/10.1136/jitc-2022-004850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710465/
https://www.ncbi.nlm.nih.gov/pubmed/36442911
http://dx.doi.org/10.1136/jitc-2022-004850

Ejemplares similares